How pneumococcal conjugate vaccines may produce antibodies that protect against serogroup 33.
Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes
This will try two different pneumococcal conjugate vaccines in healthy adults to see which one makes antibodies that can kill serogroup 33 bacteria.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT07135453 on ClinicalTrials.gov |
What this trial studies
In this Phase 4, post-licensure comparison, healthy adult participants will receive one of two licensed pneumococcal conjugate vaccines and have blood drawn before and after vaccination. Laboratory assays will measure the presence and bactericidal activity of antibodies specifically against serogroup 33. Individuals with prior pneumococcal vaccination or conditions/medications that suppress immunity are excluded. The study is conducted at the University of Alabama at Birmingham in collaboration with Merck.
Who should consider this trial
Good fit: Healthy adults with no prior pneumococcal vaccination and no chronic diseases or medications that suppress the immune system are ideal candidates.
Not a fit: People who are immunocompromised, have chronic immune-impacting conditions, or who have already received a pneumococcal vaccine are unlikely to qualify or benefit from this protocol.
Why it matters
Potential benefit: If successful, the results could show that an existing pneumococcal conjugate vaccine provides cross-protection against serogroup 33 and guide vaccine choice or future vaccine design.
How similar studies have performed: Some prior work has shown pneumococcal conjugate vaccines can induce cross-reactive antibodies, but protection specifically against serogroup 33 remains uncertain.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy adult Exclusion Criteria: * No prior history of pneumococcal vaccination * No immunosuppressing medications or chronic diseases that affect immune function
Where this trial is running
Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama, United States (Recruiting)
Study contacts
- Study coordinator: David LaFon, MD
- Email: dlafon@uabmc.edu
- Phone: 2059343411
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.